|
 |
Alpha 1-proteinaseThis page contains recent news articles, when available, and an overview of Alpha 1-proteinase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Committee for Orphan Medicinal Products (COMP) and has granted orphan drug designation to Talecris’ alpha-1 proteinase inhibitor (human) for inhalation Business Wire (press release), Talecris Biotherapeutics Receives Orphan Drug Designation for ... - Jul 31, 2008 ...granted orphan drug designation to Talecris' alpha-1 proteinase inhibitor (human) for inhalation use in the treatment of congenital Alpha1-Antitrypsin Pharmaceutical Processing, Talecris Biotherapeutics erhält von der Europäischen Kommission ... - Jul 24, 2008 Orphan Medicinal Products (COMP) [Komitee für Arzneimittel für seltene Leiden] gefolgt ist und dem Alpha-1-Proteinase-Hemmer (für Menschen) von Talecirs Business Wire (press release), Orphan News :: People - May 19, 2008 Ms. Biggs began therapy with CSL Behring's Zemaira, a next-generation Alpha-1 proteinase inhibitor proven to raise and maintain levels of alpha-1. Checkbiotech.org (press release), Talecris Biotherapeutics Celebrates 20th Anniversary Of Launch - Feb 25, 2008 Prolastin is indicated for chronic augmentation therapy of individuals having congenital deficiency of alpha-1 proteinase inhibitor with clinically Pharmaceutical Online (press release), Baxter executives complete Israel visit - Nov 29, 2007 However, Kamada can offer us its next-generation product (the reference is to Alpha-1 Antitrypsin (AAT) drug Alpha-1 Proteinase Inhibitor (API) for the Globes, �页�调色版 - Nov 14, 2007 ...to Alpha-1 Proteinase Inhibitor products or their components and individuals with selective iga deficiencies who have known antibodies against iga. 金�界, The Web Marketing Association Names www.Prolastin.com Best ... - Nov 12, 2007 Prolastin ® is indicated for chronic augmentation therapy of individuals having congenital deficiency of alpha-1 proteinase inhibitor with clinically Business Wire (press release), Kamada Is Pursuing US Market With Its Aerosolized AAT - Oct 22, 2007 The AAT drug, also known as API (Alpha-1 Proteinase Inhibitor), is currently indicated for treating Congenital Emphysema. This disease, caused by an inborn Business Wire (press release), Study Demonstrates Aerosolized Prolastin Using Unique Nebulizer ... - Sep 18, 2007 ..."The aim of aerosolized alpha-1 proteinase inhibitor is to achieve homogeneous drug deposition within the periphery of the lungs," said Steve Petteway, PharmaLive.com (press release), Kamada raises NIS 40m as options exercised; net loss grows - Aug 29, 2007 The company is currently carrying out Phase III clinical trials for its injectable Alpha-1 Antitrypsin (AAT) drug Alpha-1 Proteinase Inhibitor (API) for the Globes, Crucell Announces Second Quarter 2007 Results - Aug 13, 2007 Crucell is currently the exclusive distributor of Talecris' Prolastin® (alpha-1 proteinase inhibitor) in 10 Western European countries. CNNMoney.com Kamada's API wins EMEA OK for cystic fibrosis trial - Jul 8, 2007 Therapeutics Daily (subscription) (press release),...company's flagship product, an inhalable Alpha-1 Antitrypsin (AAT) drug Alpha-1 Proteinase Inhibitor (API) for the treatment of cystic fibrosis. Baxter in talks to buy Kamada for $150-200m - Jul 9, 2007 Globes,...to tens of millions of dollars, under which Baxter will obtain some rights to Kamada’s Alpha-1 Proteinase Inhibitor (API) for treating lung diseases. Crucell Announces European Protein Distribution Deal with Talecris ... - Apr 3, 2007 PharmaLive.com (press release),Under the terms of the agreement, Crucell will serve as the exclusive distributor of Talecris' Prolastin® (alpha-1 proteinase inhibitor) in 9 Western Crucell enters distribution deal - Apr 3, 2007 Pharmaceutical Business ReviewProlastin is indicated for chronic augmentation therapy of individuals having hereditary deficiency of alpha-1 proteinase inhibitor with clinically Kamada Begins Phase III Clinical Trial In The US With Its Alpha-1 ... - Mar 28, 2007 Medical News Today (press release),...also known as Alpha-1 Proteinase Inhibitor (API). The clinical trial, which follows FDA-approved protocol, will include 50 patients from the US Crucell in Distribution Deal with Talecris - Apr 3, 2007 Reuters.uk,..."Crucell will serve as the exclusive distributor of Talecris' Prolastin (alpha-1 proteinase inhibitor) in 9 Western European countries, replacing current Hospitals, Healthcare Providers to Save with Premier Plasma ... - Jan 3, 2007 dBusinessNews Charlotte (press release),...various coagulation factor products including Factor VIII and Factor IX; alpha-1 proteinase inhibitor; antithrombin III; and biosurgery products. Kamada begins human trial of respiratory drug - Nov 27, 2006 Pharmaceutical Business ReviewIsraeli biopharmaceutical firm Kamada has begun human phase I trials of an inhaled formulation of Alpha 1-Proteinase Inhibitor for congenital emphysema. Kamada begins human trial of respiratory drug - Nov 28, 2006 Pharmaceutical Business ReviewIsraeli bio-pharmaceutical Kamada has begun human phase I trials of an inhaled formulation of its drug, alpha 1-proteinase inhibitor (API), for congenital Kamada Begins Phase I Clinical Trials of Its Aerosolized API ... - Nov 27, 2006 PharmaLive.com (press release),...announced today that it has begun human Phase I trials of an inhaled formulation of its flagship drug, Alpha 1-Proteinase Inhibitor (API). : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |